氨甲酰磷酸合成酶1作为对乙酰氨基酚诱导的急性肝衰竭患者预后生物标志物的作用
研究利用ALF研究组收集的血清样本(103例对乙酰氨基酚相关、167例非对乙酰氨基酚相关急性肝衰竭,共764份血清),检测氨甲酰磷酸合成酶1(CPS1)水平。对乙酰氨基酚相关患者CPS1显著更高,且CPS1可提高ALFSG预后指数对21天无移植生存的预测准确性,提示其作为潜在预后生物标志物。
要点
- 对乙酰氨基酚相关急性肝衰竭患者血清CPS1水平显著高于非对乙酰氨基酚患者(P < .0001)。
- 对乙酰氨基酚相关患者中,接受肝移植或21天内死亡者CPS1水平高于自发存活者(P = .01)。
- CPS1可提高ALFSG预后指数预测对乙酰氨基酚相关急性肝衰竭21天无移植生存的准确性。
核心结论
- 血清CPS1测定为评估对乙酰氨基酚诱导的急性肝衰竭患者提供了新的潜在预后生物标志物。
研究设计与样本
- 使用酶联免疫吸附试验和免疫印迹法检测ALF研究组收集的急性肝损伤和急性肝衰竭患者血清CPS1水平,共103例对乙酰氨基酚相关和167例非对乙酰氨基酚相关病因,检测764份血清样本。
- 通过受试者工作特征曲线下面积分析比较加入CPS1与原始ALFSG预后指数的预测性能。
主要发现
- 对乙酰氨基酚相关患者的CPS1值显著高于非对乙酰氨基酚患者(P < .0001)。
- 对乙酰氨基酚相关患者中,接受肝移植或住院21天内死亡者CPS1水平高于自发存活者(P = .01)。
- CPS1酶联免疫吸附试验值的逻辑回归和受试者工作特征曲线下面积分析提高了ALFSG预后指数的准确性,该指数在对乙酰氨基酚相关而非非对乙酰氨基酚相关急性肝衰竭中预测21天无移植生存优于终末期肝病模型。
- 比较第3天与第1天水平,对乙酰氨基酚相关移植/死亡患者中更高比例出现CPS1升高而非丙氨酸转氨酶或天冬氨酸转氨酶升高(P < .05)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Carbamoyl phosphate synthetase 1 (CPS1) is a highly abundant mitochondrial urea cycle enzyme that is expressed primarily in hepatocytes. CPS1 is constitutively and physiologically secreted into bile but is released into the bloodstream upon acute liver injury (ALI). Given its abundance and known short half-life, we tested the hypothesis that it may serve as a prognostic serum biomarker in the setting of acute liver failure (ALF). METHODS: CPS1 levels were determined using enzyme-linked immunosorbent assay and immunoblotting of sera collected by the ALF Study Group (ALFSG) from patients with ALI and ALF (103 patients with acetaminophen and 167 non-acetaminophen ALF etiologies). A total of 764 serum samples were examined. The inclusion of CPS1 was compared with the original ALFSG Prognostic Index by area under the receiver operating characteristic curve analysis. RESULTS: CPS1 values for acetaminophen-related patients were significantly higher than for non-acetaminophen patients (P < .0001). Acetaminophen-related patients who received a liver transplant or died within 21 days of hospitalization exhibited higher CPS1 levels than patients who spontaneously survived (P = .01). Logistic regression and area under the receiver operating characteristic analysis of CPS1 enzyme-linked immunosorbent assay values improved the accuracy of the ALFSG Prognostic Index, which performed better than the Model for End-Stage Liver Disease, in predicting 21-day transplant-free survival for acetaminophen- but not non-acetaminophen-related ALF. An increase of CPS1 but not alanine transaminase or aspartate transaminase, when comparing day 3 with day 1 levels was found in a higher percentage of acetaminophen transplanted/dead patients (P < .05). CONCLUSION: Serum CPS1 determination provides a new potential prognostic biomarker to assess patients with acetaminophen-induced ALF.
引用
- Kwan R, Chen L, Park MJ, et al. The Role of Carbamoyl Phosphate Synthetase 1 as a Prognostic Biomarker in Patients With Acetaminophen-induced Acute Liver Failure. Clin Gastroenterol Hepatol. 2023. PMID: 37054752. doi:10.1016/j.cgh.2023.03.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。